Feasibility and Efficacy of dose adjusted Melphalan ¨C Prednisone ¨C Bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed Multiple Myeloma; a non-randomised phase II study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

25 Jun 2017 Results (n=140) presented at the 22nd Congress of the European Haematology Association.
06 Dec 2016 Results of first planned analysis on discontinuation rate (n=100) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
25 Nov 2013 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com